Beyond the target pathogen: ecological effects of the hospital formulary

被引:38
|
作者
Goldstein, Ellie J. C. [1 ]
机构
[1] David Geffen Sch Med UCLA, RM Alden Res Lab, Santa Monica, CA USA
关键词
carbapenem; Clostridium difficile infection; collateral damage; susceptibility breakpoint; CLOSTRIDIUM-DIFFICILE INFECTION; COMPARATIVE CLINICAL-TRIALS; HEALTH-CARE EPIDEMIOLOGY; ANTIBIOTIC-RESISTANCE; DISEASES-SOCIETY; UNITED-STATES; INTRAABDOMINAL INFECTIONS; ANTIMICROBIAL RESISTANCE; ERYTHROMYCIN RESISTANCE; PSEUDOMONAS-AERUGINOSA;
D O I
10.1097/01.qco.0000393485.17894.4c
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review Antibiotic therapy has the potential for intended as well as unintended consequences due to ecological effects that extend beyond the target pathogen. This review examines some of the collateral damage and collateral benefit that may occur when using antibiotic therapy. Recent findings Antibiotics excreted in the gastrointestinal tract cause alterations of the indigenous flora. Such disruptions may increase the risk of colonization and overgrowth of pathogenic bacteria, including resistant species, with the potential for serious infection for an individual patient as well as possible hospital-wide dissemination resulting in local outbreaks of infection. For example, Clostridium difficile infection (CDI), and particularly associated diarrhea and colitis, is a potentially serious and growing problem in hospitals worldwide, and is associated with disruption of gut flora through use of broad-spectrum antibiotics, especially those with antianaerobic activity. Infection control measures and improved antibiotic stewardship are key measures for CDI prevention. Another example is the risk of intestinal colonization and overgrowth with resistant bacteria, which is heightened in surgical patients requiring antimicrobial therapy for intraabdominal infections. Results from two Optimizing Intra-Abdominal Surgery with Invanz studies (OASIS-I and OASIS-II) suggested emergence of resistant Enterobacteriaceae was less likely in these patients treated with ertapenem than in those treated with ceftriaxone/metronidazole or piperacillin/tazobactam. Finally, recent studies have reported that increased use of a nonpseudomonal carbapenem such as ertapenem does not reduce the susceptibility of Pseudomonas aeruginosa to pseudomonal carbapenems, for example, imipenem or meropenem. In fact, data from one study showed increased ertapenem/decreased imipenem use was associated with improved susceptibility of P. aeruginosa to imipenem, probably due to decreased selective pressure for resistant species. Summary Improper antibiotic use can be associated with detrimental effects related to the ecological impacts of these drugs. Improved antibiotic stewardship and appropriate infection control measures are key to minimization of the collateral damage associated with antibiotic therapy and may even have collateral benefits.
引用
收藏
页码:S21 / S31
页数:11
相关论文
共 50 条
  • [21] Optimizing the diabetic formulary: Beyond aspirin and insulin
    Marso, SP
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (04) : 652 - 661
  • [22] THE HOSPITAL FORMULARY:A TYPE OF ESSENTIAL DRUG PROGRAM
    Marcus M.Reidenberg
    中国临床药理学杂志, 1993, (01) : 8 - 9
  • [23] CHIRALTY AND HOSPITAL FORMULARY: A SECOND LIFE FOR A BLOCKBUSTER
    Vernaz-Hegi, N.
    Girardin, F.
    Muscionico, D.
    Salomon, J. L.
    Bonnabry, P.
    VALUE IN HEALTH, 2008, 11 (06) : A379 - A379
  • [24] A TEAM-APPROACH TO HOSPITAL FORMULARY REPLACEMENT
    LEE, JY
    CARLSON, JA
    CHAMBERLAIN, MA
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) : 239 - 242
  • [25] Biosimilar Drugs and the Hospital Formulary: A Canadian Experience
    Fenna, Jennifer
    Watkins, Kathy
    Guirguis, Micheal
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2019, 72 (02): : 145 - 150
  • [26] DOCUMENTATION OF AMERICAN HOSPITAL FORMULARY SERVICE MONOGRAPHS
    REILLY, MJ
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1973, 30 (11): : 1073 - 1073
  • [27] ASSESSMENT OF ESSENTIAL DRUGS IN THE MEDICINES FORMULARY HOSPITAL
    Lachhab, Z.
    Serragui, S.
    Cherrah, Y.
    Ahid, S.
    VALUE IN HEALTH, 2017, 20 (05) : A51 - A51
  • [28] Implementing the new oral anticoagulants into the hospital formulary
    Palladino, Michael
    Thomson, Lynda
    Swift, Brian
    Merli, Geno J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S127 - S132
  • [29] Budget impact of adding doripenem to a hospital formulary
    Kongnakorn, T.
    Merchant, S.
    Akhras, K.
    Ingham, M.
    Mody, S.
    Mwamburi, M.
    Caro, J. J.
    VALUE IN HEALTH, 2008, 11 (03) : A94 - A94
  • [30] THERAPEUTIC HOSPITAL FORMULARY FOR A BETTER USE OF DRUGS
    BERTI, T
    BOZZINI, L
    MARTINI, N
    MINELLIBERTAZZONI, E
    SCANAGATTA, A
    VELO, GP
    PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1979, 11 (05): : 379 - 387